Effects of Tiotropium Bromide Combined with Symbicort Turbuhaler on Lung Function, Exercise Tolerance and Adverse Reactions in Patients with Chronic Obstructive Pulmonary Disease
LIU Bin, RAN Xiangui, XING Qingfeng, et al
Fuyang People's Hospital, Anhui Fuyang 236000, China
Abstract：Objective: To explore the effects of tiotropium bromide combined with budesonide formoterol powder inhalant (trade name: symbicort turbuhaler) on lung function, exercise tolerance and adverse reactions in patients with chronic obstructive pulmonary disease (COPD). Methods: A total of 118 patients with acute exacerbation of COPD were selected and randomly grouped (observation group, n=59; control group, n=59). All patients were given routine symptomatic treatment, and control group was given tiotropium inhalation treatment, and observation group was given symbicort turbuhaler on the basis of above treatment. The lung function indexes, exercise tolerance, arterial gas blood analysis indexes and serum biochemical indexes were observed in the two groups before treatment and after 14 d of treatment, and the medicinal safety was evaluated in the two groups. Results: After 14 d of treatment, the lung function indexes of mean pulmonary artery pressure (MPAP), pulmonary artery systolic pressure (PASP) and pulmonary artery diastolic pressure (PADP) were significantly decreased in the the two groups (P<0.05), and the 6min walking distance (6MWD) score was improved (P<0.05), and the arterial gas blood analysis index of arterial partial pressure of oxygen (PaO2) was significantly increased (P<0.05) while the arterial partial pressure of carbon dioxide (PaCO2) was significantly decreased (P<0.05), and the levels of serum tissue inhibitor of metalloproteinase-1 (TIMP-1), matrix metalloproteinase-9 (MMP-9) and advanced glycation end products (AGEs) were significantly decreased in the two groups (P<0.05) while the level of soluble receptor for advanced glycation end-product (sRAGE) was significantly increased (P<0.05), and the changes of the above indicators in observation group were significantly greater than those in control group (P<0.05). The total incidence rates of adverse reactions in observation group and control group were 10.17% and 6.78% respectively (P>0.05). Conclusions: Tiotropium bromide combined with symbicort turbuhaler can treat patients with acute exacerbation of COPD, and it can significantly improve lung function, enhance exercise tolerance, and reduce lung inflammatory response, and it has good clinical medicinal safety, thus it is worthy of promotion.
刘斌, 冉献贵, 邢青峰, 徐琳琳. 噻托溴铵联合信必可都保治疗对慢阻肺患者肺功能和运动耐量及不良反应的影响[J]. 河北医学, 2019, 25(7): 1108-1112.
LIU Bin, RAN Xiangui, XING Qingfeng, et al. Effects of Tiotropium Bromide Combined with Symbicort Turbuhaler on Lung Function, Exercise Tolerance and Adverse Reactions in Patients with Chronic Obstructive Pulmonary Disease. HeBei Med, 2019, 25(7): 1108-1112.
2019, Vol. 25 
冀公网安备13080202000677号